Watt, Maureen <br/><br/>
A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.  [electronic resource] 

 -  Infection  Oct 2016 
 - 599-606 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1439-0973 
<br/><br/><label>Standard No.: </label>10.1007/s15010-016-0894-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aminoglycosides--economics<br/>Anti-Bacterial Agents--economics<br/>Clostridioides difficile--drug effects<br/>Cost-Benefit Analysis<br/>Enterocolitis, Pseudomembranous--drug therapy<br/>Fidaxomicin<br/>Germany<br/>Humans<br/>Markov Chains<br/>Recurrence